ACI's Sunshine Act Compliance & Aggregate Spend Reporting
HCP Reporting Compliance and Risk Mitigation Strategies for Biopharmaceutical and Medical Device Manufacturers
Companies are under urgent pressure to swiftly implement and manage a complete and integrated aggregate spend system before tracking commences in August 2013 and the first reports are due in March 2014. Gain advanced strategies to incorporate immediately to meet the massive challenge of satisfying both federal and state disclosure requirements in an expedited timeframe.
Time is a luxury life sciences companies cannot afford to waste as the March 2014 deadline for initial reporting and submission quickly approaches. Complying with complicated and evolving federal, state, and global spend disclosure laws demands a massive amount of effort and resources, and companies must be compliant when doing business throughout the U.S. and abroad or else face severe monetary penalties and loss of crucial market share. ACI’s 5th Annual Forum on Sunshine Act Compliance & Aggregate Spend Reporting will save you time and money as a frontline faculty of drug and device manufacturers, government enforcers, and policy advisors help you formulate real-world, cost-effective strategies to streamline your systems and capture and report accurate and compliant spend data.
Paul Hastings partner Palmina Fava is a featured speaker for this program.
For additional information and to register, visit